Allergy Therapeutics PLC revealed plans to raise 19 mln stg via a share placing at 100 pence per share, to fund the final clinical trials of its hayfever vaccine Pollinex Quatro.
Allergy Therapeutics PLC revealed plans to raise 19 mln stg via a share placing at 100 pence per share, to fund the final clinical trials of its hayfever vaccine Pollinex Quatro.